Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from complications from cancer treatment to nutritional disorders and diseases brought on by viral infections and immune malfunction.
Disease targets include large patient populations with inflammatory bowel diseases (ulcerative colitis and Crohn’s), digestive disorders (exocrine pancreatic insufficiency in cystic fibrosis patients), and the COVID-19 pandemic (acute and long-haul COVID-related GI infections).
IN THE NEWS
|
Octo 21, 2021
First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Patients with Immune Checkpoint Inhibitor-Associated Colitis
|
|
Octo 19, 2021
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
|
|
Octo 14, 2021
First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
|
